Skip to main content

Table 2 Tissue-specific effective half-lives derived from activity concentration at day 1 and day 3, and absorbed doses per injected activity for the 3TP reference method (n = 279)

From: Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT

 

Effective half-life (h)a

Absorbed dose per injected activity (Gy/GBq)

Kidney

46.6 [36.3–55.7] (24.3–161.0)

0.54 [0.31–0.88] (0.21–4.25)

Bone marrowself

72.3 [44.9–161.0] (29.4–161.0)

0.031 [0.014–0.087] (0.004–0.258)

Bone marrowcrossb

66.9 [50.3–91.6] (24.6–121.6)

0.0030 [0.0016–0.0059] (0.0005–0.0161)

Bone marrowtotal

0.035 [0.018–0.092] (0.009–0.262)

Tumormaxc

100.9 [60.0–158.4] (27.7–161.0)

3.8 [1.0–8.6] (0.1–32.0)

  1. Data is presented as median [interdecile range] (range)
  2. aIn cases of biological accumulation of activity (kidney, n = 1; bone marrowself, n = 30; tumormax, n = 26), effective half-life was assumed to be equal to the physical half-life of 177Lu, i.e., 161 h
  3. bBone marrow cross-dose is derived from the gamma contribution of whole-body activity retention over time
  4. cn = 278